The wet age-related macular degeneration (AMD) therapy market has long been dominated by three VEGF inhibitors: Roche / Genentech / Chugai’s Avastin, Roche / Genentech / Novartis’s Lucentis, and Regeneron / Bayer HealthCare / Santen’s Eylea. Competition was expected to increase with the U.S. launch of Novartis’s Beovu in October 2019, but safety concerns have slowed Beovu’s uptake. Nevertheless, the mainstay anti-VEGF therapies will face competition from the growing number of therapies for wet AMD in the late-stage pipeline, including biosimilar agents. In contrast to wet AMD, the management of dry AMD is limited because no prescription therapies are approved for this large subpopulation. Despite recent setbacks in the clinical development of some late-stage dry AMD therapies, other agents are progressing, increasing the likelihood that an effective therapy may soon emerge.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 31 country-specific interviews with thought-leading retinal specialists. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Total prevalence of late AMD by country, segmented by GA and wet AMD subpopulations, including diagnosed and drug-treated rates.
Forecast: Ten-year, annualized, drug-level sales and patient share of key GA and wet AMD therapies through 2030, segmented by brands / biosimilars and epidemiological subpopulations.
Emerging therapies: Phase III / PR: 11 drugs; Phase II: 14 drugs; coverage of select Phase I products.
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.